A Phase 2 interventional study of Blinatumomab in B-cell Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 75 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-10.
Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing blinatumomab in Burkitt Lymphoma — 16 open to participants now, 23 under way, 8 of them phase 3. blinatumomab · Burkitt Lymphoma.
Among the 35 studies testing blinatumomab in Burkitt Lymphoma, this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 17 in phase 2, and was the 1st registered.
977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.
Browse Burkitt Lymphoma studies →16 of the 35 studies testing blinatumomab in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Austria, Belgium, Czechia and 18 more countries
Ages 1+
City of Hope Medical Center · Sites in United States
Ages 12–55
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages up to 365 days
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 130 Burkitt Lymphoma studies recruiting now, 40 (31%) set no upper age limit and 77 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 8
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 36 across 766 interventional studies indexed under Burkitt Lymphoma.
Median enrollment 52 across the 35 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amgen Research (Munich) GmbH, one of the names counted as Amgen. Under that name alone:
Amgen Research (Munich) GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
Amgen has 5 studies filed under Burkitt Lymphoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing blinatumomab in Burkitt Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT03739814National Cancer Institute (NCI)Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies testing blinatumomab in Burkitt Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
The detection of minimal residual disease (MRD) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of adult ALL. No standard treatments are available for patients with MRD-positive B-precursor ALL. Blinatumomab (MT103) is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against cluster of differentiation (CD)19 expressing cells. The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
Participants will receive up to four 4-week cycles of intravenous blinatumomab treatment followed by an infusion-free period of 14 days. A safety follow-up will be performed 30 days after the end of the last infusion and efficacy follow-ups will occur until 24 months after treatment start. Participants will be followed for up to 5 years after the start of treatment for survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
Drug: Blinatumomab
Continuous intravenous infusion
Also known as: AMG 103, MT103, BLINCYTO™
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle
At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. Complete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.
Time frame: During the first cycle (6 weeks)
Hematological Relapse-free Survival (RFS)
Hematological RFS was measured from first dose of blinatumomab until the first assessment of documented relapse (either hematological or extramedullary), secondary leukemia, or death due to any cause. Participants without a documented relapse, or death due to any cause were censored at the time of their last hematological assessment. Participants who received chemotherapy for relapsed or persistent MRD or for any other reason after treatment with blinatumomab, or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse, or death occurred were censored at the start of chemotherapy or HSCT, respectively. Hematological relapse was defined as unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia (whichever occurred first). The 18-month Kaplan-Meier estimate of hematological RFS is reported.
Time frame: 18 months, up to the data cut-off date of 05 August 2015
Overall Survival
Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.
Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
The mortality rate within 100 days after allogeneic HSCT was defined as the Kaplan-Meier estimate of the percentage of participants dying within 100 days after the day of the first allogeneic HSCT.
Time frame: 100 days after HSCT, as of the data cut-off date of 05 August 2015
Time to Hematological Relapse
Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).
Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
Duration of Complete MRD Response
The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status. Participants who received chemotherapy or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse were censored at the start of chemotherapy or HSCT, respectively. MRD relapse is defined as the reappearance of individual rearrangements of Ig- or TCR-genes ≥ lower limit of quantification (LLOQ) for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4. Hematological relapse is defined as the unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological or microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia.
Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders
MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.
Time frame: Baseline and end of cycle 1 (6 weeks)
Number of Participants With Adverse Events
Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.
Time frame: From the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.
Change From Baseline in EORTC-QLQ-C30 Scales
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. The maximum changes from baseline to cycles 1 through 4 and the change from baseline to the end of the core study are reported.
Time frame: Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales
The EQ-5D is a self-administered questionnaire which captures 3 basic types of information: a descriptive profile (health state index) and the overall health rating using a visual analog scale. The health state index measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression on scales from no problems (score = 1), some problems (score = 2), to extreme problems (score = 3). For each dimension the mean change from baseline was calculated at the end of each treatment cycle and at the end of the core study. The maximum observed change from baseline during cycles 1 to 4 and the change from baseline at the end of the core study are reported for each dimension.
Time frame: Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
Time frame: From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months
Resource Utilization: Duration of Hospitalization
Time frame: From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.
This study was open to adults with a diagnosis of minimal residual disease (MRD; ≥ 10-³ leukemic cells) -positive B-precursor acute lymphoblastic leukemia (ALL) who were in complete hematologic remission.
| Milestone | Blinatumomab |
|---|---|
| Started | 116 |
| Completed | 48 |
| Not completed | 68 |
| Withdrew: Death | 67 |
| Withdrew: Withdrawal by subject | 1 |
At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. Complete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.
| percentage of participants | Blinatumomab |
|---|---|
| Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle | 77.0 (68.1 to 84.4) |
Hematological RFS was measured from first dose of blinatumomab until the first assessment of documented relapse (either hematological or extramedullary), secondary leukemia, or death due to any cause. Participants without a documented relapse, or death due to any cause were censored at the time of their last hematological assessment. Participants who received chemotherapy for relapsed or persistent MRD or for any other reason after treatment with blinatumomab, or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse, or death occurred were censored at the start of chemotherapy or HSCT, respectively. Hematological relapse was defined as unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia (whichever occurred first). The 18-month Kaplan-Meier estimate of hematological RFS is reported.
| percentage of participants | Blinatumomab |
|---|---|
| Hematological Relapse-free Survival (RFS) | 54 (33 to 70) |
Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.
| months | Blinatumomab |
|---|---|
| Overall Survival | 36.5 (19.2 to NA) |
The mortality rate within 100 days after allogeneic HSCT was defined as the Kaplan-Meier estimate of the percentage of participants dying within 100 days after the day of the first allogeneic HSCT.
| percentage of participants | Blinatumomab |
|---|---|
| 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant | 7 (3 to 15) |
Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).
| months | Blinatumomab |
|---|---|
| Time to Hematological Relapse | NA (7.1 to NA) |
The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status. Participants who received chemotherapy or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse were censored at the start of chemotherapy or HSCT, respectively. MRD relapse is defined as the reappearance of individual rearrangements of Ig- or TCR-genes ≥ lower limit of quantification (LLOQ) for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4. Hematological relapse is defined as the unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological or microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia.
| months | Blinatumomab |
|---|---|
| Duration of Complete MRD Response | 45.0 (6.5 to 45.0) |
MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.
| Participants | Cycle 1 MRD 10^-5 | Cycle 1 MRD 10^-4 | Cycle 1 MRD 10^-3 | Cycle 1 MRD 10^-2 | Cycle 1 MRD 10^-1 | Cycle 1 MRD Unknown |
|---|---|---|---|---|---|---|
| Baseline MRD Unknown | 0 | 1 | 0 | — | 0 | 0 |
| Baseline MRD 10^-5 | 0 | 0 | 0 | — | 0 | 0 |
| Baseline MRD 10^-4 | 0 | 1 | 0 | — | 0 | 0 |
| Baseline MRD 10^-3 | 1 | 6 | 2 | — | 1 | 0 |
| Baseline MRD 10^-2 | 0 | 5 | 2 | — | 1 | 0 |
| Baseline MRD 10^-1 | 1 | 0 | 0 | — | 0 | 2 |
Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.
| participants | Blinatumomab |
|---|---|
| Any adverse event | 116 |
| Serious adverse events | 73 |
| Adverse events ≥ CTC grade 3 | 71 |
| Adverse events ≥ CTC grade 4 | 33 |
| Fatal adverse events | 2 |
| AEs leading to discontinuation of blinatumomab | 20 |
| AEs leading to interruption of blinatumomab | 36 |
| Treatment-related adverse events | 112 |
| Treatment-related serious adverse events | 60 |
| Treatment-related adverse events ≥ CTC grade 3 | 60 |
| Treatment-related adverse events ≥ CTC grade 4 | 26 |
| Treatment-related fatal adverse events | 1 |
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. The maximum changes from baseline to cycles 1 through 4 and the change from baseline to the end of the core study are reported.
| units on a scale | Maximum Change From Baseline in Cycles 1 - 4 | Change From Baseline at End of Core Study |
|---|---|---|
| Global Health Status | 9.0 ± 4.2 | 3.9 ± 2.4 |
| Physical Functioning | 2.6 ± 2.3 | 2.2 ± 1.9 |
| Role Functioning | 12.2 ± 8.5 | 1.4 ± 3.5 |
| Emotional Functioning | 6.5 ± 4.9 | 5.3 ± 2.7 |
| Cognitive Functioning | -3.3 ± 5.2 | -2.3 ± 2.5 |
| Social Functioning | 12.2 ± 8.5 | 14.9 ± 3.8 |
| Fatigue Symptom | -5.9 ± 5.5 | -5.4 ± 2.4 |
| Nausea and Vomiting Symptom | -4.5 ± 4.7 | -2.3 ± 2.0 |
| Pain Symptom | 3.8 ± 3.6 | -1.4 ± 2.7 |
| Dyspnea Symptom | -9.0 ± 4.7 | -0.9 ± 2.9 |
| Insomnia Symptom | -2.6 ± 3.2 | 3.7 ± 3.5 |
| Appetite Loss Symptom | -17.8 ± 6.4 | -9.1 ± 3.4 |
| Constipation Symptom | -5.1 ± 3.6 | 0.0 ± 2.2 |
| Diarrhea Symptom | 5.1 ± 5.5 | 0.0 ± 2.3 |
| Financial Difficulties Symptom | -5.1 ± 4.8 | -0.9 ± 2.9 |
The EQ-5D is a self-administered questionnaire which captures 3 basic types of information: a descriptive profile (health state index) and the overall health rating using a visual analog scale. The health state index measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression on scales from no problems (score = 1), some problems (score = 2), to extreme problems (score = 3). For each dimension the mean change from baseline was calculated at the end of each treatment cycle and at the end of the core study. The maximum observed change from baseline during cycles 1 to 4 and the change from baseline at the end of the core study are reported for each dimension.
| units on a scale | Maximum Change From Baseline in Cycles 1 - 4 | Change From Baseline at End of Core Study |
|---|---|---|
| Mobility | -0.2 ± 0.1 | 0.0 ± 0.1 |
| Self-care | -0.1 ± 0.1 | 0.0 ± 0.0 |
| Usual Activities | -0.1 ± 0.1 | -0.1 ± 0.1 |
| Pain/Discomfort | -0.2 ± 0.2 | -0.1 ± 0.1 |
| Anxiety/Depression | -0.2 ± 0.1 | -0.1 ± 0.1 |
| Participants | Blinatumomab |
|---|---|
| Overall | 14 |
| Cycle 1 | 5 |
| Cycle 2 | 8 |
| Cycle 3 | 0 |
| Cycle 4 | 1 |
| Follow-up period | 0 |
| days | Blinatumomab |
|---|---|
| Resource Utilization: Duration of Hospitalization | 14.0 (3 to 63) |
Collected over All-cause mortality is reported from enrollment until the end of the follow-up period; median (minimum, maximum) time on study was 33.8 (1, 62) months. Adverse events are reported from the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinatumomab | 67/116 (57.8%) | 73/116 (62.9%) | 111/116 (95.7%) |
| Event | Blinatumomab |
|---|---|
| PyrexiaGeneral disorders | 17/116 |
| TremorNervous system disorders | 8/116 |
| AphasiaNervous system disorders | 6/116 |
| EncephalopathyNervous system disorders | 6/116 |
| NeutropeniaBlood and lymphatic system disorders | 5/116 |
| OverdoseInjury, poisoning and procedural complications | 5/116 |
| C-reactive protein increasedInvestigations | 4/116 |
| Device related infectionInfections and infestations | 3/116 |
| Staphylococcal infectionInfections and infestations | 3/116 |
| SeizureNervous system disorders | 3/116 |
| Event | Blinatumomab |
|---|---|
| PyrexiaGeneral disorders | 99/116 |
| HeadacheNervous system disorders | 44/116 |
| ChillsGeneral disorders | 30/116 |
| TremorNervous system disorders | 28/116 |
| NauseaGastrointestinal disorders | 27/116 |
| FatigueGeneral disorders | 27/116 |
| VomitingGastrointestinal disorders | 26/116 |
| DiarrhoeaGastrointestinal disorders | 22/116 |
| HypokalaemiaMetabolism and nutrition disorders | 18/116 |
| InsomniaPsychiatric disorders | 17/116 |
Full analysis set (all participants who received any infusion of blinatumomab)
| Age, Continuous(years) | Blinatumomab |
|---|---|
| Mean | 44.6 ± 16.4 |
| Age, Customized(participants) | Blinatumomab |
|---|---|
| ≥ 18 and <35 years | 36 |
| ≥ 35 and < 55 years | 41 |
| ≥ 55 and < 65 years | 24 |
| ≥ 65 years | 15 |
| Sex: Female, Male(Participants) | Blinatumomab |
|---|---|
| Female | 48 |
| Male | 68 |
| Race/Ethnicity, Customized(participants) | Blinatumomab |
|---|---|
| White | 102 |
| Asian | 1 |
| Mixed | 1 |
| Unknown | 12 |
| Philadelphia Chromosome Disease Status(participants) | Blinatumomab |
|---|---|
| Positive | 5 |
| Negative | 111 |
| Confirmed t(4;11) Translocation / MLL-AF4+ ALL(Participants) | Blinatumomab |
|---|---|
| Yes | 5 |
| No | 88 |
| Unknown | 23 |
| MRD Level at Baseline by Central Laboratory(participants) | Blinatumomab |
|---|---|
| ≥ 10^-1 and < 1 | 9 |
| ≥ 10^-2 and < 10^-1 | 45 |
| ≥ 10^-3 and < 10^-2 | 52 |
| < 10^-3 | 3 |
| Below Lower Limit of Quantification | 5 |
| Unknown | 2 |
| White Blood Cells at First Diagnosis(participants) | Blinatumomab |
|---|---|
| ≤ 30,000/mL | 78 |
| > 30,000/mL | 18 |
| Unknown | 20 |
The record gives a start of Nov 2010, a primary completion of Feb 2014 and a completion of Jan 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Amgen Research (Munich) GmbH →